1[1]Dar M, Abdel WZ, Vervaert C, et al. Trans duction with the murine interferon gamma gene leads to long-term immunological memory[J ]. Ann Surg Oncol, 1996,3:247 - 54
2[2]Zeinab AW, Christina W, Dina H, et al. A phase I clinical trial of immunotherapy with i nterferon-r gene-modified autologous melanoma cells[J ]. Cancer, 1997,80: 401 -412
3[3]Berd D, Henry C, Maguire Jr. Autologous hapten-modified melanoma vaccine as post surgical adjuvant treatment after resection of nodal metastases[J]. Journal of Clinical Oncology, 1997,15: 2359 - 2370
4[4]Morton DL, Barth A. Vaccine therapy for nalignant melanoma CA[J ]. Cancer J Clin,1996,46: 225 - 244
5[5]Hsueh EC,Gupta R K, Karen Qi, et al . Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine [ J ].J Clin Oncol,1998,16: 2913 - 2920
6[6]Jager D,Jager E, Knuth A. Vaccination for malignant melanoma: recent developments[J]. Oncology, 2001,60:1 - 7
7[7]Hsueh EC, Nathanson L, Foshag L J, et al . Active Specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases [ J ]. Cancer, 1999,85: 2160 - 2169
8[8]Moller P, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the antimelanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase 1 study [ J ]. British Joural of Cancer, 1998,77:1907 1916
9[9]Hsueh EC, Nathanson L , Leland J, et al . Active specific immunotherapy with polyvalent melanoma cell Vaccine for patients with In-Transit melanoma meastases[ J ]. Cancer,1999,85:2160 2169
10[10]Hseh EC, Nizze A, Essner R, et al. Adjuvant immunotherapy with polyvalent melanoma cell vaccine ( PMCV ) prolongs survival after complete resection of distant melanoma metastases: Matched pair analysis[J]. Proc Am Soc Clin On-col, 1997, 16:492
